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ABSTRACT 
Objective: The objective of the present study was to develop an optimized gastroretentive floating drug delivery 
system of Olmesartan Medoxomil and investigate the effect of hydrophilic retardant on invitro release by using 32 
full factorial design.  Methods: Floating tablets of olmesartan medoxomil were prepared by direct compression 
method using effervescent technique by employing two different grades of HPMC. (HPMC K4M and HPMC 
K100M). Sodium bicarbonate was incorporated as gas generating agent. The concentration of HPMC K4M (X1) 
and concentration  of  HPMC K100M (X2) were selected as independent variables. The floating lag time,  total 
floating time and t ime taken to  80% drug release were  selected  as  dependent   variables. Targets were 
defined for each response so as to select the optimim formula using numerical optimization. All  the  floating  
matrix  tablets formulations  were  subjected  to  pre-compression  and  post-compression  parameter evaluation. 
Result: The results indicated that the concentration of X1  and X2 significantly affected the floating lag time, 
total floating time and T80. Drug release properties were affected by concentration of HPMC K4M  and  HPMC 
K100M. Optimized  formulation F9 with increased equal concentrations of X1 and X2 and sodium bicarbonate 
showed good physical propreties with short lag time of 55sec and T80 of  18 hrs.  Conclusion: The drug release 
from the tablet was sustained and non fickian transport  of  drug from the t ablet  was  confirmed.  The 
optimized formulation was stable when kept for short term stability study for one month. 
Keywords: Olmesartan Medoxomil, Effervescent technique, Direct Compression Method, 32 Full Factorial 
Design, Short Term Stability Study. 
Introduction 
 
 
Controlled release drug administration means not only 
the prolongation of the duration of drug delivery, 
similar to the objective in sustained release and 
prolonged release, but the term also implies the 
predictability and reproducibility of drug release 
kinetics. Oral controlled release drug delivery system 
that provides the continuous oral delivery of drugs at 
predictable and reproducible kinetics for a pre-
determined period throughout the course of GI transit. 
Gastroretentive dosage forms are the systems that can 
stay in the gastric region for several hours and thus, 
prolong the gastric residence time of the drugs. After 
oral administration, such a dosage form is retained in 
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the stomach and releases the drug in a controlled and 
sustained manner so that the drug can be supplied 
continuously in the upper GIT. This prolonged gastric 
retention improves bioavailability, decreases drug 
wastage, and improves solubility of drugs that are less 
soluble in a high pH environment[1]. Gastric emptying 
of dosage forms is an extremely variable process and 
ability to prolong and control the emptying time is a 
valuable asset for dosage forms, which reside in the 
stomach for a longer period of time than 
conventional dosage forms.  Several  difficulties  are  
faced  in  designing  controlled  release systems  for  
better  absorption  and  enhanced   bioavailability.  
One of such difficulties is the inability to confine the 
dosage form in the desired area of the gastrointestinal 
tract. One of the most feasible approaches for 
achieving and predictable drug delivery  profile  in 
GIT is to control the GRT so that gastric emptying 
process can be extended from few minutes to 12 hr 
using GRDF’s that offers  new  and  better option  for 
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drug therapy[2].Olmesartan medoxomil, a prodrug, is 
hydrolyzed to olmesartan during absorption from the 
gastrointestinal tract. Olmesartan is a selective AT1 
subtype angiotensin II receptor antagonist. Angiotensin 
II is formed from angiotensin I in a reaction catalyzed 
by angiotensin converting enzyme (ACE, kininase II). 
Angiotensin II is the principal pressor agent of the 
renin-angiotensin system, with effects that include 
vasoconstriction, stimulation of synthesis and release 
of aldosterone, cardiac stimulation and renal 
reabsorption of sodium. Olmesartan blocks the 
vasoconstrictor effects of angiotensin II by selectively 
blocking the binding of angiotensin II to the AT1 
receptor in vascular smooth muscle. Its action is, 
therefore, independent of the pathways for angiotensin 
II synthesis. Olmesartan medoxomilis indicated for the 
treatment of mild to moderate essential hypertension. 
[3]..The absolute bioavailability of olmesartan is 
approximately 26%. After oral administration, the peak 
plasma concentration (Cmax) of olmesartan is reached 
after 1 to 2 hours. Food does not affect the 
bioavailability of olmesartan.Olmesartan medoxomil 
inhibits the pressor effect of an angiotensin II infusion 
in a dose- dependent manner at doses of 2.5 to 40 mg. 
The inhibition was 90% at doses of olmesartan 
medoxomil >40 mg 24 hours post dose.  
 
Materials  and  methods 
 
Olmesartan medoxomil was obtained as a gift sample 
from Akums Pharma Ltd. Haridwar. HPMC K4M, 
HPMC K100M were obtained from Aglomed pharma, 
Roorkee. All other reagents used were of analytical 
grade.  
 
Drug excipients compatibility study  
 
Fourier Transform Infrared (FTIR)  
 
Drug excipients interactions play vital role in the 
release of drug from the formulation. Fourier 
Transform Infrared spectroscopy has been used to 
study the physical and chemical interaction between 
the excipients used.  FTIR technique has been used to 
study the physical and chemical interaction between 
drurg and excipients used. [4] 
Powder flow property 
 
The flow properties of powder were determined 
included the following: bulk density, tapped density , 
carr’s index, Hausner’s ratio and angle of repose. All 
the above properties were measured according to USP 
XXXI. [5] 
 
Preparation of standard curve of olmesartan 
medxomil in methanol 
 
Accurately weighed olmesartan medoxomil (10 mg) 
was placed in 100 ml volumetric flask, 10 ml of  
methanol was added to it and sonicate for 1 minute and 
then made up the volume to 100 ml with methanol. 
From the above solution, 1 ml of solution was pipette 
out and diluted to 10 ml with methanol. The resultant 
solution obtained was 10 µg/ml and was scanned in UV 
range of 200 to 400 nm. Olmesartan medoxomil  
showed maximum absorbance at 257 nm. Thus, 257 
nm was taken as λmax. 
 
Preparation of floating tablets of olmesartan 
medoxomil 
 
The composition of different formulations of 
Olmesartan Medoxomil floating tablets is shown in 
table 1. Direct compression method had been employed 
to prepare floating tablets of Olmesartan Medoxomil  
with HPMC K4M and HPMC K100M . All ingradients 
were weighed accurately and passed through mesh #60. 
In order to mix thoroughly polymer and drug blended 
geometrically in mortar pestle for 15 mins and then 
sodium bicarbonate, citric acid, magnesium sterate, talc 
and lactose were mixed one by one. After thorough 
mixing these ingradients the powder blend was passed 
through mess #44. The tablets were compressed on 
rotary tablet press. [6]. 
 
Experimental Design 
 
A 32 full factorial design was used for the optimization. 
 
Optimization of floating tablets of Olmesartan 
Medoxomil by 32 full factorial design 
 
 In the present study three levels two factors, full 
factorial design was employed for the optimization of 
floating tablets of olmesartan medoxomil. The 
concentration of HPMC K4M and HPMC K100M were 
selected as independent variable and floating lag time, 
total floating time and T80 were selected as dependent 
variables 
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Table no 1: Full factorial design layout 
 
Batch code X1 X2  
 F1 -1 -1  
 F2 -1 0  
 F3 -1 1  
 F4 0 -1  
 F5 0 0  
 F6 0 1  
 
F7 1 -1  
 F8 1 0  
 F9 1 1  
 
  
                      X1 code for amount of HPMC K4M and X2 code for amount of HPMCK100M. 
 
Table no 2: Coded values X1 code for amount of HPMC K4M and X2 Code for amount of 
HPMCK100M 
 
Coded value Amount of HPMC K4M 
in mg  (X1) 
Amount  of HPMCK100M in mg 
(X2) 
 
 
-1 0 0  
 
0 40 40  
 
1 80 80  
 
  Formulation of factorial batches and Statistical 
modeling for optimization  
 
A three level, two factor experimental design as shown 
below described the proportion in which independent 
variables- concentration of HPMC K4M and HPMC 
K100M was used in the formulation. The concentration 
of polymer was varied at three level 0, 40 mg and 80 
mg. floating lag time, total floating time and T80 of 9 
formulations were analysed. 
 
Table no 3: statistical model for optimization 
Factor                         Level   
Independent 
variables  
   High(1)  Medium(0)    Low (-1) Dependent variable 
HPMC K4M 80 40 0 Floating lag time 
HPMC K100M 80 40 0 Total floating time & 
 
   T 80 
 
Table no 4: Composition Of Floating Tablet Of Olmesartan Medoxomil 
Ingradients  Formulations code (All the quantities are in mg.) 
 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Olmesartan 
medoxomil 
50 50 50 50 50 50 50 50 50 
HPMC K4M 0 0 0 40 40 40 80 80 80 
HPMC K100M 0 40 80 0 40 80 0 40 80 
Sodium bicarbonate 70 70 70 70 70 70 70 70 70 
Magnesium stearate 8 8 8 8 8 8 8 8 8 
Talc  7 7 7 7 7 7 7 7 7 
Lactose 230 190 150 190 150 110 150 110 70 
Citric acid 35 35 35 35 35 35 35 35 35 
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2
The run or formulation which are designed based on 
factorial design are evaluated for the response. The 
response values are subjected to multiple regression 
analysis to find out the relationship between the factor 
used and the response value obtained. The response 
values subjected for this analysis is floating lag time, 
total floating time and T80.  The multiple regression 
analysis was done using DESIGN EXPERT 9.0.3.1 D- 
optimal type. Which is specially meant for this 
optimization. Analysis of data was carried out using 
ANOVA and the individual parameter was evaluated 
with F test , using the regression coefficient of factor , 
the polynomial equation for each response is generated. 
Y = b0  + b1X1  + b2X2  + b12X1X2  + b11X1
2 
+ b22X2
2
 
Where Y is the dependent variable, b0  is the 
arithmetic mean response and bi  is the  estimated  
coefficient  for  the  factor  Xi. The  main  effects  
(X1  and  X2) represent the average result of 
changing one factor at a time from its low to high 
value. The interaction terms (X1X2) show how the 
response changes when two factors are 
simultaneously changed. The polynomial 
terms(X12 and X 2) are included to investigate 
nonlinearity.On the basis of preliminary trials a 32 
full factorial design was employed to study the effect 
of independent variables ie concentration of HPMC 
K4M and HPMC K100M on dependent variable ie 
floating lag time, total floating time and T80.Analysis 
of variance, contour and RSM plots represent the 
effect of the independent variables graphically 
 
Regression Analysis Equation for LT 
 
Fig1:Contour plot to study the effect of two HPMC grade polymer concentrations on  floating lag time
 
 
Fig 2: RSM plot to study the effect of two HPMC grade polymer concentrations on floating lag time 
LT= 174.4166-1.4729X1-1.55208X2+0.0195X1X2
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Regression Analysis for total floating time 
 
Fig 3: Contour plot to study the effect of two HPMC grade polymer concentrations on total floating time 
 
Fig 4: RSM plot to study the effect of two HPMC grade polymer concentrations on total floating  time 
TFT= 0.7778+0.32083X1+0.27500X2-1.87500X1X2-1.97917X12-1.6667X22 
Total floating time gives correlation co-efficient 
0.7778. The P value for  variable  X1  and  X2  were  
0.0127 and  0.0059  respectively  (P<0.05),  it 
indicate that X1 and X2 variable  shown significant 
effect on drug release Combination co-efficient was 
positive and the P value less than 0.05, which  
indicates that combination of independent variable 
showed significant effect on  floating lag time.The 
co-efficient of X1 and X2 were positive indicate 
that when concentration of both the variable increase 
than total floating  time was increased. 
Regression Analysis for T80 
 
Fig 5: Contour plot to study the effect of two HPMC grade polymer concentrations on T80. 
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Fig 6: RSM plot to study the effect of two HPMC grade polymer concentrations on T80. 
 
           T80=   4.3333+0.07500X1+0.10000X2 
T80 gives correlation co-efficient 4.3333. The P 
value for  variable  X1  and  X2  were  0.0030 and  
0.0007  respectively  (P<0.05),  it indicate that X1 
and X2 variable  shown significant effect on drug 
release. Combination co-efficient was positive and 
the P value less than 0.05, which indicates that 
combination of independent variable showed 
significant effect on  T80. 
  
Fig 7: Comparision of TFT, LT and T80 of different formulation batches with respect to polymer 
concentration. 
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Fig 8: Plot depicting target solutions after optimization 
 
Fig 9: RSM plot depicting the predicted desirability value after optimization 
 
Evaluation of floating tablet: The prepared tablets were evaluated for the following parameters: 
  
Thickness of Tablets 
The thickness of six tablets was measured using 
Vernier calipers. The extent to which the thickness 
of each tablet deviated from ± 5% of the standard 
value was determined. [7] 
  
Hardness 
The hardness of the tablet was determined by 
Monsento hardness tester.  Six tablets from each 
batch were selected and evaluated, and the average 
value with standard deviation was recorded.[8] 
 
Friability 
The Friability of tablets was performed in a Roche 
Friabilator. It consists of a plastic chamber that 
revolves at 25 rpm.  
Ten tablets were weighed together and then placed 
in the chamber. The friabilator was operated for 100 
revolutions and the tablets were subjected to the 
combined effects of abrasion  and shock because the 
plastic chamber carrying the tablets drops them at a 
distance of six  inches with every revolution. The 
tablets  are  then  dusted  and  re-weighed.  The  
friability  (F)  is  given  by  the  formula. [9] 
 
F= W initial – W final * 100 
W initial 
 
Weight Variation 
Twenty tablets were individually weighed and 
average weight was calculated.The individual weight 
was compared to the average weight. The tablets pass 
the test if not more than two tablets are outside the 
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percentage limit  and  if  no  tablet  differs  by  more  
than  two  times  the  percentage  the percentage limit. 
  
In-vitro buoyancy studies 
The in vitro buoyancy was determined by floating 
lag time method. The tablets were placed in 100 ml 
beaker containing 0.1 N HCl. The time required for 
the tablets to float was determined as floating lag 
time. Total floating time was also determined. [10] 
 
In-vitro Dissolution Studies 
In vitro dissolution study was performed by using 
USP Type  II Apparatus (Paddle type)   at 100 rpm. 
Dissolution test was performed using 0.1N HCL as 
dissolution medium and the temperature was 
maintained at 37 ± 0.5ºC. Aliquot of dissolution 
medium was withdrawn at specific time intervals 
2,4,6,8,10,12,14,16,18,20,22,24. 
The samples were filtered through a 0.45  
membrane filter and diluted to a suitable 
concentration with 0.1N HCl.  Absorbance of these 
solutions was measured   at   257   nm   UV   
spectrophotometer.   Cumulative percentage of drug 
release was calculated using the equation obtained 
from a standard curve. [11] 
 
Swelling index 
The swelling index of tablets was determined in 
0.1N HCl (pH 1.2) at room temperature.  The 
swollen weight of the tablets was determined at 
predefined time intervals. The swelling index was 
calculated by the following equation: 
Swelling index = (Wt – W0/W0)*100 
Where, W0 is the initial weight of tablet, and Wt is 
the weight of the tablet at time t.[12] 
  
Kinetic modeling and mechanism of drug release 
To know the mechanism of drug release from these 
formulations, The data were treated according to 
first-order (log cumulative percentage of drug 
remaining vs time), Higuchi’s (cumulative percentage 
of drug released vs square root of time), Korsmeyer 
(log cumulative percentage of drug released vs log 
time), equations along with zero order (cumulative 
amount of drug released vs time) pattern. [13-15] 
 
Accelerated stability study 
The tablets of best batch were packed in aluminum 
pouch and charged for accelerated stability studies at 
40 °C and 75% RH for 1 month in a humidity 
jar.[16]
Result and discusssion 
 
Standard curve of  Olmesartan  Medoxomil 
Standard curve of olmesartan was prepared in 
methanol. Standard curve data ere subjected to linear 
regression analysis. R2 value were found to be 0.970 
which indicate linearity 
 
Fig 10: Standard curve of olmesartan Medoxomil 
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Fig 11: FTIR of  Olmesartan Medoxomil 
Drug Polymer interaction Studies 
  
Fig 12: FTIR of the formulation 
Olmesartan showed characterstic peak at 2974cm-1 
(aliphatic C-H Streching),3039 cm-1 (aromatic C-H 
Streching), 3271cm-1 (broad peak intermolecular 
Hydrogen bond), 3720 cm-1 (C=O of carboxylic 
group), 1483 cm-1 (C-N Streching). The formulation  
containing polymer showed all the peaks of Olmesartan 
Medoxomil  with no change in intensity. 
                           
 
Table no 5: Evaluation parameter of tablets of different batches 
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Tablets 
Batch 
Weight 
variation test 
(mg.) 
 
Thickness 
(mm) 
 
Hardness 
(kg/cm2) 
 
Friability 
       (%) 
F1 398.47±2.31 4.25±0.31 5.0±0.40 0.45±0.020 
F2 398.77±2.13 3.94±.02 4.5±0.20 0.36±0.015 
F3         399.21±4.2 3.96±0.04 4.5±0.30 0.38±0.020 
F4 398.37±1.01 
 
4.03±0.05 5.0±0.40 0.28±0.030 
F5 399.43±2.31 3.81±0.06 5.0±0.35 0.27±0.060 
F6 400.20±0.41 4.34±0.23 5.5±0.50 0.32±0.035 
F7 400.12±1.32 4.08±0.07 5.0±0.20 0.22±0.040 
F8 401.53±0.86 3.93±0.06 4.0±0.30 0.28±0.015 
F9 401.74±1.39 4.12±0.07 5.0±0.20 0.23±0.020 
Table no 6: In vitro buoyancy studies 
 Batch Floating lag time(sec) Floating time 
 
 
F1 200 0 hrs  
 
F2 74 10hrs  
 
F3 68 12hrs.  
 
F4 100 11hrs.  
 
F5 90 16hrs.  
 
F6 54 15hrs.  
 
F7 62 14hrs.  
 
F8 59 15hrs  
 
F9 55 14hrs  
 
  
 
The in-vitro buoyancy was determined by floating lag time method. The tablets were placed in 100 ml beaker 
containing 0.1 N HCl. The time required for the tablets to float was determined as floating lag time.  
                                                   
                  At  0 sec                                                                               after 40 secs 
 
In vitro buoyancy study showed that all the batches from F1 
to F9 have floating lag time less than 4 minutes because of 
evolution and entrapment of carbondioxide inside the 
hydrated polymer matrices, resulting from the interaction 
between gas generating agent and dissolution medium which 
led to lowering the density of matrices enabling the tablets to 
float. On the other hand, as a solvent front penetrated the 
polymer layer, swelling of HPMC K4M and HPMC K100M 
caused to increase in volume of tablet resulted in net 
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reduction in density of the tablet, which prolonged the duration of floatation up to 18 hrs. 
 
 
After 16 hrs 
Fig 13: Buoyancy studies of tablet at different time interval 
                                          
                                                  Table no 7: Dissolution studies of different batches 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Invitro buoyancy study showed that all the batches 
from F1 to F9 have floating lag time less than 4 
minutes because of evolution and entrapment of 
carbondi oxide inside the hydrated polymer matrices, 
resulting from the interaction between gas generating 
agent and dissolution medium which led to lowering  
the density of matrices enabling the tablets to float.[16-
18] On the other hand, as a solvent front penetrated the 
polymer layer, swelling of HPMC K4M and 
HPMC.K100M caused to increase in volume of tablet 
resulted in net reduction in density of the tablet, which 
prolonged the duration of floatation up to 18 hrs. 
Among these formulations F9 give the desired release 
and retarded the 80%  drug release for 18 hrs. 
     
TIME   (in hrs) 
                                 
                          CUMMULATIVE PERCENT RELEASE 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
 
         
0  0 0 0 0 0 0 0 0 0 
2 38.39 18.34 17.32 22.43 19.21 17.32 19.43 20.11 11.92 
3 79.54 42.12 30.21 41.56 38.42 34.42 40.24 36.75 16.93 
5 98.22 65.86 39.42 66.76 46.34 47.59 48.25 41.44 21.84 
7  74.41 48.64 80 59.52 53.54 56.11 53.33 32.06 
8  80.64 56.42 88.53 63.54 58.67 64.66 60.51 39.46 
10  92.45 61.36 94.36 68.98 64.77 73.22 68.67 48.47 
12  98.55 67.48 97.87 72.32 70.52 78.98 75.34 55.12 
13   72.49  79.87 75.33 85.33 81.43 59.49 
14   78.87  87.41 80.32 89.89 89.54 62.11 
15   85.64  91 85.66 94.31 93.77 68.42 
16   92.48  96.73 91.29 97.75 98.24 71.45 
17   98.56   98.43   78.74 
18         81.72 
19         88.89 
20         93.21 
21         97.54 
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Fig 14: In vitro dissolution  studies of different formulation batches 
 
 
 
Fig 15: Dissolution profile of formulations F1 to F9 
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Table no 8: Invitro drug release kinetics study 
Model Zero order First order Higuchi plot Korsmeyer peppas 
R2 0.997 0.728 0.922 0.992 
Slope  4.527 11.51 23.47 0.908 
Intercept  1.284 -6.627 -21.02 0.769 
 
The data were treated according to first-order (log 
cumulative percentage of drug remaining  vs  time),  
Higuchi’s (cumulative  percentage  of  drug  released  
vs square root of time),  Korsmeyer (log cumulative 
percentage of drug released vs log time), equations 
along with zero order (cumulative  amount of drug 
released vs time) .The dissolution profile of the best 
batch was fitted to zero-order, first-order, Higuchi and 
korsmeyer models to ascertain the kinetic modeling of 
drug release. It may be concluded that the drug release 
from gastro retentive olmesartan medoxomil tablet is 
explained by zero model because R2 value of zero 
order  model has 0.997. The values n in korsmeyer 
peppas equation is 0.769 which is greater than 0.50, 
thus we can conclude that dissolution follows non 
fickain diffusion. 
Swelling index  
Swelling index of the tablet include the absorption of 
liquid medium then increases the weight of the tablet. 
This is very important characteristics of the polymer 
which control the drug release from the formulation via 
diffusion from the studies it was found that increase the 
concentration of HPMC K4M increases the swelling 
property.F9 showed maximum swelling among all 
HPMC containing formulations. HPMC K4M and 
HPMC K100M tablet when in contact with dissolution 
medium swell due to breakage of hydrogen bond 
between the polymer chain and form a thick gel layer 
and eroded simultaneously. This result indicated that 
the swelling index of all the formulations changed after 
different time interval. 
 
Fig 16: Swelling studies of formulation batches 
 
Accelerated stability studies 
 
Gastro retentive tablets of olmesartan medoxomil 
formulated in the present study were subjected to 
accelerated stability studies in Aluminum / 
Aluminum pouch pack as aluminum strip is 
considered the best protecting packaging material but 
in the present study simulation was made using 
aluminum foil pouch. As the dosage form is 
formulated for site-specific drug delivery to stomach, 
no change should occur in its floating lag time and 
drug dissolution profile. Dose dumping and failure of 
buoyancy are probable effects anticipated during the 
stability study of such dosage forms. The tablets of 
best batch F9 were packed in aluminum pouch and 
charged for accelerated stability studies at 40 °C and 
75% RH for 1 months in a humidity jar. 
[19-22]
0
20
40
60
80
100
120
140
160
180
0 5 10 15 20
swelling index
F1
F2
F3
F4
F5
F6
F7
F8
F9
 
Asian Pac. J. Health Sci., 2015; 2(1): 133-147                                         e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Sharma and Goyal ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(1): 133-147 
www.apjhs.com      146 
 
 
Fig 17: Accelerated stability studies of the optimized batch 
 
Conclusion 
 
In the present work floating tablets of Olmesartan 
Medoxomil were prepared by direct compression. All 
the tablets were subjected to weight variation, 
hardness, friability,diisolution, swelling index, drug 
excipient interaction studies. The tablets were found to 
be good in their integritywithout any chipping, capping 
and sticking. Formulation F9 showed good result than 
rest of the formulations according to targets obtained. 
Formulation F9 showed best result with required 
floating lag time of 55 secs, total floating time of 14  
hrs and T80 of18 hrs. drug release was decreased with 
increased concentration of polymers. IR spectroscopic 
studies indicated that there was no drug excipient 
interactions. Kinetic studies for optimized formulation 
F9 follows zero order and Higuchi model release 
systems. Zero order release describes the system where 
the drug release rateis independent of its concentration 
of dissolved substance. 
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